Cite
HARVARD Citation
Petrylak, D. et al. (2020). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet oncology. 21 (1), pp. 105-120. [Online].